New data suggest that the risk from covid infection in patients with multiple sclerosis (MS) is no different than the risk in general population. Severe outcomes are associated with older age, black race, kidney disease and greater disability.
Disease modifying therapies do not worsen the course of the disease with the probable exception of anti -CD 20 drugs. In some case (ie interferons) MS treatment may act protectively against the virus.
These results presented in the ECTRIMS conference in September are in general reassuring for the majority of MS patients as long as they keep the anti- Covid guidelines!